In this interview, Jamin Brahmbhatt, MD, gives his take on several studies of orchialgia and chronic prostatitis/chronic pelvic pain syndrome presented at the 2018 AUA annual meeting.
AUA Street Team
Arthur L. Burnett, II, MD, MBA, discusses some of the significant differences between the 2018 and 2005 AUA guidelines on ED as well as how the new guideline addresses novel treatments that are not currently FDA approved.
In this video, Benjamin M. Brucker, MD, explains the use of clinical care pathways to manage overactive bladder and outlines the benefits of SUFU’s Overactive Bladder Clinical Care Pathway.
Anne E. Calvaresi, DNP, CRNP, RNFA, also discusses best practices that urologists and APPs can follow to ensure they work together well as a team and offers her opinion on the controversy surrounding the use of APPs for performing certain urologic procedures.
In this video, Alan J. Wein, MD, PhD, discusses recent developments in the management of nocturia, including a new FDA-approved agent; underlying causes; and the role of a voiding diary in patient care.
Peter Black, MD, discusses which patients are currently eligible for immunotherapy, how the indications are likely to expand, some of the common side effects of immunotherapy and their incidence, and the availability of tools to determine which patients are suitable candidates for treatment.
In this interview, Steven A. Kaplan, MD, highlights the key updates to the 2018 guideline that differentiates it from the AUA’s 2010 guideline on this topic.